<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02631941</url>
  </required_header>
  <id_info>
    <org_study_id>Z7200J04</org_study_id>
    <secondary_id>2015-003233-95</secondary_id>
    <nct_id>NCT02631941</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate Z7200 Pharmacokinetics Profile</brief_title>
  <official_title>An Open-Label, Randomized, Five-Period Cross-over, Single-dose Study to Compare Pharmacokinetics Profiles of Z7200 Midium Strength and Symbicort Turbohaler, With and Without Charcoal Blockade in Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zambon SpA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zambon SpA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The pharmacokinetics study aims to evaluate the safety of Z7200 (budesonide/formoterol) in&#xD;
      comparison with Symbicort Turbohaler (budesonide/formoterol), assessing the bioequivalence of&#xD;
      the two products. Namely the study will compare the total systemic bioavailability (as an&#xD;
      indicator of safety), and it will compare the pulmonary bioavailability (as a possible&#xD;
      surrogate indicator of efficacy). This study will be performed in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to the last detectable level (AUC0-t) of budesonide and formoterol without charcoal blockade.</measure>
    <time_frame>0-24h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma level (Cmax) of budesonide and formoterol without charcoal blockade</measure>
    <time_frame>0-24h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to the last detectable level (AUC0-t) of budesonide and formoterol with charcoal blockade</measure>
    <time_frame>0-24h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma level (Cmax) of budesonide and formoterol with charcoal blockade</measure>
    <time_frame>0-24h</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Z7200</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose (two inhalations)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Symbicort Turbohaler</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single dose (two inhalations)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Z7200 with charcoal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose (two inhalations)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Symbicort Turbohaler with charcoal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single dose (two inhalations)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Symbicort Turbohaler replicate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single dose (two inhalations)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Z7200</intervention_name>
    <arm_group_label>Z7200</arm_group_label>
    <other_name>budesonide/formoterol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Symbicort Turbohaler</intervention_name>
    <arm_group_label>Symbicort Turbohaler</arm_group_label>
    <other_name>budesonide/formoterol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Z7200 with charcoal</intervention_name>
    <arm_group_label>Z7200 with charcoal</arm_group_label>
    <other_name>budesonide/formoterol with coadministration of charcoal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Symbicort Turbohaler with charcoal</intervention_name>
    <arm_group_label>Symbicort Turbohaler with charcoal</arm_group_label>
    <other_name>budesonide/formoterol with coadministration of charcoal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Symbicort Turbohaler replicate</intervention_name>
    <arm_group_label>Symbicort Turbohaler replicate</arm_group_label>
    <other_name>budesonide/formoterol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          -  Male or female 18 to 45 years of age.&#xD;
&#xD;
          -  If female, is currently not pregnant/breast feeding/ or attempting to become pregnant&#xD;
             has a negative serum pregnancy test, or is of non-childbearing potential or is of&#xD;
             child-bearing potential, willing to commit to using a consistent and acceptable method&#xD;
             of birth control or is of child-bearing potential and not sexually active&#xD;
&#xD;
          -  Body mass index (BMI) of 18.0 to 32.0 kg/m² inclusive and a body weight ≥50 kg.&#xD;
&#xD;
          -  10 years or more past history of cigarette, &lt;=5 pack year&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  Forced Expiratory Volume in 1 sec (FEV1) value less than 80% of the predicted value&#xD;
             and FEV1/FVC (Forced Vital Capacity) ratio &lt;0.7.&#xD;
&#xD;
          -  History or current evidence of a clinically significant disease or disorder capable of&#xD;
             altering the absorption, metabolism, distribution or elimination of drugs.&#xD;
&#xD;
          -  History or current evidence of a clinically significant disease including, but not&#xD;
             limited to: cardiovascular, hepatic, renal, haematological, neuropsychological,&#xD;
             endocrine, gastrointestinal or pulmonary.&#xD;
&#xD;
          -  Presence of glaucoma, cataracts, ocular herpes simplex, malignancy, regardless of the&#xD;
             clinical significance or current stability of the disease.&#xD;
&#xD;
          -  positive tests for Human Immunodeficiency Virus (HIV), Hepatitis B and Hepatitis C.&#xD;
&#xD;
          -  Bacterial or viral infection of the upper respiratory tract (including the common cold&#xD;
             and flu), sinus, or middle ear within 2 weeks of dosing.&#xD;
&#xD;
          -  Lower respiratory tract infection/pneumonia within the past 3 months.&#xD;
&#xD;
          -  Presence of any disease or condition or regular concomitant treatment (including&#xD;
             vitamins and herbal products) known to interfere with the absorption, distribution,&#xD;
             metabolism or excretion of drugs.&#xD;
&#xD;
          -  Screening haemoglobin value of less than 1g/dL above the Lower Limit of Normality&#xD;
&#xD;
          -  History of recurrent vasovagal collapses.&#xD;
&#xD;
          -  History of anaphylactic/anaphylactoid reactions.&#xD;
&#xD;
          -  History of seizures including febrile seizures excluding childhood febrile&#xD;
             convulsions.&#xD;
&#xD;
          -  Unable to demonstrate proper inhalation techniques involved in using the delivery&#xD;
             devices at screening.&#xD;
&#xD;
          -  Exposure to any investigational drug within 90 days of the Screening Visit.&#xD;
&#xD;
          -  Known or suspected hypersensitivity or idiosyncratic reaction to any steroid, any β2&#xD;
             agonist; allergy to milk protein.&#xD;
&#xD;
          -  Use of an inhaled corticosteroid within 30 days or systemic corticosteroid within 60&#xD;
             days of the Screening Visit.&#xD;
&#xD;
          -  Use of medications or herbal medicines that are strong cytochrome P450 3A4 (CYP3A4)&#xD;
             inhibitors or inducers within 30 days prior to Screening Visit&#xD;
&#xD;
          -  Any clinically significant abnormal laboratory value or physical finding that may&#xD;
             interfere with the interpretation of test results or cause a health risk for the&#xD;
             subject if he/she participates in the study.&#xD;
&#xD;
          -  Use of caffeine containing beverages more than 5 cups/day.&#xD;
&#xD;
          -  Recent or current (suspected) drug abuse or positive result in the drugs abuse test.&#xD;
&#xD;
          -  Recent or current alcohol abuse (regular drinking more than 21 units per week for&#xD;
             males and more than 14 units per week for females)&#xD;
&#xD;
          -  Predictable poor compliance, intolerance to charcoal solution, or inability to&#xD;
             communicate well with the study centre personnel or inability to participate in all&#xD;
             treatment periods.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharan Sidhu, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quotient Clinical Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quotient Clinical Ltd</name>
      <address>
        <city>Ruddington</city>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>December 14, 2015</study_first_submitted>
  <study_first_submitted_qc>December 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2015</study_first_posted>
  <last_update_submitted>September 28, 2016</last_update_submitted>
  <last_update_submitted_qc>September 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
    <mesh_term>Charcoal</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 6, 2021</submitted>
    <returned>November 4, 2021</returned>
    <submitted>November 12, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

